AstraZeneca PLC (AZN) Fundamental Analysis
AstraZeneca PLC is in a high-growth phase, expanding revenue 9% year-over-year as it scales. It is solidly profitable, with a latest net margin of 17%. Cash generation is healthy, funding the business from its own operations. The latest filing shows a mixed picture across the four dimensions.
Beat Index assesses AstraZeneca PLC across seventeen analysis tabs, spanning market multiples, revenue and income, margins, cash flow, returns, liquidity and leverage, working capital, intrinsic value, commitments, insider activity, risk, and its latest 20-F reads strongest on profit margins and cash generation while flagging revenue growth and balance-sheet strength for closer review. Every figure is taken as-reported from SEC EDGAR filings, with no vendor adjustments.
At a glance
- PositiveProfitability: Net margin 17%
- WatchGrowth: Revenue +9% YoY
- ConcernNo red flags in the latest quarter.
Trend matrix, last 4 quarters
| Dimension | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Growth | Revenue +9% YoY | Revenue up 18% YoY | Revenue +3% YoY | Revenue up 19% YoY |
| Profitability | Net margin 17% | Net margin 13% | Net margin 13% | Net margin 7% |
| Cash Generation | FCF margin 20% | FCF margin 18% | FCF margin 20% | FCF margin 20% |
| Balance Sheet | Current ratio 0.9x (low debt, cash-generative) | Current ratio 0.9x (low debt, cash-generative) | Current ratio 0.8x (low debt, cash-generative) | Current ratio 0.9x (low debt, cash-generative) |
Quarterly financials
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $58.74B | $54.07B | $45.81B | $44.35B | $37.42B |
| Cash & equivalents | $5.71B | $5.49B | $5.84B | $6.17B | $6.33B |
| Net income | $10.22B | $7.04B | $5.96B | $3.29B | $112.0M |
| Operating cash flow | $14.57B | $11.86B | $10.35B | $9.81B | $5.96B |
| Free cash flow | $11.77B | $9.94B | $8.98B | $8.72B | $4.87B |
Figures in USD, as reported to the SEC. Longer history is available in the full analysis.
What's inside the full dashboard
Seventeen analysis tabs, all sourced from SEC filings, no estimates.
- Market Multiples: What buyers have actually paid for this business, week by week, against what they pay today.
- Cash Flow: Free cash flow generation and operating cash flow trends.
- Intrinsic Value: Discounted cash flow (DCF) valuation against your own discount rate.
- Liquidity & Leverage: Balance-sheet strength: assets, liabilities, debt and liquidity ratios.
- Margins: Gross, operating, and net profit margin analysis.
- Returns: Return on equity, return on assets, and return on invested capital.
- Revenue & Income: Revenue growth, composition, and year-over-year income trends.
- Working Capital: Working-capital efficiency, cash conversion and asset-turnover metrics.
- Risk: Debt levels, liquidity ratios, and financial risk indicators.
- Insider: Insider stock transactions and executive activity.
- Commitments: Operating leases, purchase commitments, and future obligations.
To see more, create a free account.
Create free accountUnlock the full AstraZeneca PLC dashboard
Live valuation, management commentary, and peer comparison, all sourced directly from SEC filings. Free to access.